$node = stdClass Object (
[nid] => [12203]
[vid] => [12281]
[type] => [what_new]
[status] => [1]
[created] => [1225979087]
[changed] => [1259870975]
[comment] => [2]
[promote] => [0]
[sticky] => [0]
[revision_timestamp] => [1259870975]
[title] => [Type 1 Diabetes Preclinical Testing Program (T1D-PTP)]
[body] => [<div class="field field-type-text field-field-exrternal-link-0"><div class="field-items"><div class="field-item">http://www.t1diabetes.nih.gov/T1D-PTP/</div></div></div><div class="field field-type-text field-field-body"><div class="field-items"><div class="field-item"><p>In some cases, additional preclinical testing is needed to validate potential therapies under disease-specific conditions and in multiple animal models before therapeutics can enter the <a href="http://www.t1diabetes.nih.gov/T1D-RAID/">T1D-RAID</a> development pipeline. In recognition of this need, NIDDK recently established the <strong>Type 1 Diabetes Preclinical Testing Program (<a href="http://www.t1diabetes.nih.gov/T1D-PTP/">T1D-PTP</a>)</strong> to provide investigators with access to the established facilities and expertise needed to extend, enhance and validate preclinical studies of promising new therapeutics. The T1D-PTP program currently supports two contracts, which are separate from each other and from the T1D-RAID NCI contract resources mentioned above, to assist in preclinical development of therapeutics for T1D:</p>
<ul>
<li>Agents to be tested for Preclinical Efficacy in Prevention or Reversal of Type 1 Diabetes in Rodent Models. Type 1 Diabetes Preclinical Testing Program (T1D-PTP) <a href="http://grants.nih.gov/grants/guide/notice-files/NOT-DK-08-012.html">(NOT-DK-08-012)</a></li>
<li>Testing for Preclinical Efficacy in Prevention or Reversal of Diabetic Complications in Rodent Models <a href="http://grants.nih.gov/grants/guide/notice-files/NOT-DK-07-013.html">(NOT-DK-07-013)</a></li>
</ul>
<p> </p>
<p>The T1D-RAID and T1D-PTP are programs intended to remove the most common barriers to progress in identification and development of new therapies for Type 1 Diabetes. The common goal of these programs is to support and provide for the preclinical work necessary to obtain "proof of principle" establishing that a new molecule or novel approach will be a viable candidate for expanded clinical evaluation.</p>
</div></div></div>]
[log] => []
[format] => [0]
[uid] => [5]
[name] => [kristin.abraham]
[picture] => []
[data] => [a:0:{}]
[path] => [type-1-diabetes-preclinical-testing-program-t1d-ptp]
[nodewords] => []
[last_comment_timestamp] => [1225979087]
[last_comment_name] => []
[comment_count] => [0]
[taxonomy] => array (
[2283] => stdClass (
[0] => [**Recursion Detected**]
)
)
[files] => []
[field_body] => array (
[0] => array (
[value] => [<p>In some cases, additional preclinical testing is needed to validate potential therapies under disease-specific conditions and in multiple animal models before therapeutics can enter the <a href="http://www.t1diabetes.nih.gov/T1D-RAID/">T1D-RAID</a> development pipeline. In recognition of this need, NIDDK recently established the <strong>Type 1 Diabetes Preclinical Testing Program (<a href="http://www.t1diabetes.nih.gov/T1D-PTP/">T1D-PTP</a>)</strong> to provide investigators with access to the established facilities and expertise needed to extend, enhance and validate preclinical studies of promising new therapeutics. The T1D-PTP program currently supports two contracts, which are separate from each other and from the T1D-RAID NCI contract resources mentioned above, to assist in preclinical development of therapeutics for T1D:</p><ul><li>Agents to be tested for Preclinical Efficacy in Prevention or Reversal of Type 1 Diabetes in Rodent Models. Type 1 Diabetes Preclinical Testing Program (T1D-PTP) <a href="http://grants.nih.gov/grants/guide/notice-files/NOT-DK-08-012.html">(NOT-DK-08-012)</a></li><li>Testing for Preclinical Efficacy in Prevention or Reversal of Diabetic Complications in Rodent Models <a href="http://grants.nih.gov/grants/guide/notice-files/NOT-DK-07-013.html">(NOT-DK-07-013)</a></li></ul><p> </p><p>The T1D-RAID and T1D-PTP are programs intended to remove the most common barriers to progress in identification and development of new therapies for Type 1 Diabetes. The common goal of these programs is to support and provide for the preclinical work necessary to obtain "proof of principle" establishing that a new molecule or novel approach will be a viable candidate for expanded clinical evaluation.</p>]
[format] => [1]
[view] => [<p>In some cases, additional preclinical testing is needed to validate potential therapies under disease-specific conditions and in multiple animal models before therapeutics can enter the <a href="http://www.t1diabetes.nih.gov/T1D-RAID/">T1D-RAID</a> development pipeline. In recognition of this need, NIDDK recently established the <strong>Type 1 Diabetes Preclinical Testing Program (<a href="http://www.t1diabetes.nih.gov/T1D-PTP/">T1D-PTP</a>)</strong> to provide investigators with access to the established facilities and expertise needed to extend, enhance and validate preclinical studies of promising new therapeutics. The T1D-PTP program currently supports two contracts, which are separate from each other and from the T1D-RAID NCI contract resources mentioned above, to assist in preclinical development of therapeutics for T1D:</p>
<ul>
<li>Agents to be tested for Preclinical Efficacy in Prevention or Reversal of Type 1 Diabetes in Rodent Models. Type 1 Diabetes Preclinical Testing Program (T1D-PTP) <a href="http://grants.nih.gov/grants/guide/notice-files/NOT-DK-08-012.html">(NOT-DK-08-012)</a></li>
<li>Testing for Preclinical Efficacy in Prevention or Reversal of Diabetic Complications in Rodent Models <a href="http://grants.nih.gov/grants/guide/notice-files/NOT-DK-07-013.html">(NOT-DK-07-013)</a></li>
</ul>
<p> </p>
<p>The T1D-RAID and T1D-PTP are programs intended to remove the most common barriers to progress in identification and development of new therapies for Type 1 Diabetes. The common goal of these programs is to support and provide for the preclinical work necessary to obtain "proof of principle" establishing that a new molecule or novel approach will be a viable candidate for expanded clinical evaluation.</p>
]
)
)
[field_content_weight] => array (
[0] => array (
[value] => [0]
)
)
[field_exrternal_link_0] => array (
[0] => array (
[value] => [http://www.t1diabetes.nih.gov/T1D-PTP/]
[view] => [http://www.t1diabetes.nih.gov/T1D-PTP/]
)
)
[page_title] => []
[readmore] => []
[content] => array (
[field_exrternal_link_0] => array (
[#access] => [1]
[#value] => [<div class="field field-type-text field-field-exrternal-link-0"><div class="field-items"><div class="field-item">http://www.t1diabetes.nih.gov/T1D-PTP/</div></div></div>]
[#weight] => [0]
[#printed] => [1]
)
[field_content_weight] => array (
[#weight] => [0]
[#value] => []
[#access] => []
)
[field_body] => array (
[#access] => [1]
[#value] => [<div class="field field-type-text field-field-body"><div class="field-items"><div class="field-item"><p>In some cases, additional preclinical testing is needed to validate potential therapies under disease-specific conditions and in multiple animal models before therapeutics can enter the <a href="http://www.t1diabetes.nih.gov/T1D-RAID/">T1D-RAID</a> development pipeline. In recognition of this need, NIDDK recently established the <strong>Type 1 Diabetes Preclinical Testing Program (<a href="http://www.t1diabetes.nih.gov/T1D-PTP/">T1D-PTP</a>)</strong> to provide investigators with access to the established facilities and expertise needed to extend, enhance and validate preclinical studies of promising new therapeutics. The T1D-PTP program currently supports two contracts, which are separate from each other and from the T1D-RAID NCI contract resources mentioned above, to assist in preclinical development of therapeutics for T1D:</p>
<ul>
<li>Agents to be tested for Preclinical Efficacy in Prevention or Reversal of Type 1 Diabetes in Rodent Models. Type 1 Diabetes Preclinical Testing Program (T1D-PTP) <a href="http://grants.nih.gov/grants/guide/notice-files/NOT-DK-08-012.html">(NOT-DK-08-012)</a></li>
<li>Testing for Preclinical Efficacy in Prevention or Reversal of Diabetic Complications in Rodent Models <a href="http://grants.nih.gov/grants/guide/notice-files/NOT-DK-07-013.html">(NOT-DK-07-013)</a></li>
</ul>
<p> </p>
<p>The T1D-RAID and T1D-PTP are programs intended to remove the most common barriers to progress in identification and development of new therapies for Type 1 Diabetes. The common goal of these programs is to support and provide for the preclinical work necessary to obtain "proof of principle" establishing that a new molecule or novel approach will be a viable candidate for expanded clinical evaluation.</p>
</div></div></div>]
[#weight] => [0]
[#printed] => [1]
)
[body] => array (
[#weight] => [0]
[#value] => []
[#printed] => [1]
)
[#children] => [<div class="field field-type-text field-field-exrternal-link-0"><div class="field-items"><div class="field-item">http://www.t1diabetes.nih.gov/T1D-PTP/</div></div></div><div class="field field-type-text field-field-body"><div class="field-items"><div class="field-item"><p>In some cases, additional preclinical testing is needed to validate potential therapies under disease-specific conditions and in multiple animal models before therapeutics can enter the <a href="http://www.t1diabetes.nih.gov/T1D-RAID/">T1D-RAID</a> development pipeline. In recognition of this need, NIDDK recently established the <strong>Type 1 Diabetes Preclinical Testing Program (<a href="http://www.t1diabetes.nih.gov/T1D-PTP/">T1D-PTP</a>)</strong> to provide investigators with access to the established facilities and expertise needed to extend, enhance and validate preclinical studies of promising new therapeutics. The T1D-PTP program currently supports two contracts, which are separate from each other and from the T1D-RAID NCI contract resources mentioned above, to assist in preclinical development of therapeutics for T1D:</p>
<ul>
<li>Agents to be tested for Preclinical Efficacy in Prevention or Reversal of Type 1 Diabetes in Rodent Models. Type 1 Diabetes Preclinical Testing Program (T1D-PTP) <a href="http://grants.nih.gov/grants/guide/notice-files/NOT-DK-08-012.html">(NOT-DK-08-012)</a></li>
<li>Testing for Preclinical Efficacy in Prevention or Reversal of Diabetic Complications in Rodent Models <a href="http://grants.nih.gov/grants/guide/notice-files/NOT-DK-07-013.html">(NOT-DK-07-013)</a></li>
</ul>
<p> </p>
<p>The T1D-RAID and T1D-PTP are programs intended to remove the most common barriers to progress in identification and development of new therapies for Type 1 Diabetes. The common goal of these programs is to support and provide for the preclinical work necessary to obtain "proof of principle" establishing that a new molecule or novel approach will be a viable candidate for expanded clinical evaluation.</p>
</div></div></div>]
[#printed] => [1]
)
[links] => array (
[comment_forbidden] => array (
[title] => [<a href="/user/login?destination=comment/reply/12203%2523comment-form">Login</a> to post comments]
[html] => [1]
)
)
);
